Of further interest is the fact that the correlation between high mean expression of JAM-A, HER2 and FOXA1 and poor patient survival in specifically HER2-positive patients is not limited to breast cancer, but also holds true for HER2-positive gastric cancer patients. The gene discussed is FOXA1; the disease is gastric cancer.